Phorbaketal A inhibits adipogenic differentiation through the suppression of PPARγ-mediated gene transcription by TAZ

Mi Ran Byun, Cham Han Lee, Jun Ha Hwang, A. Rum Kim, Sung Ah Moon, Mi Kyung Sung, Jung Rae Roh, Eun Sook Hwang, Jeong-Ho Hong

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Obesity causes several metabolic diseases, including diabetes. Adipogenic differentiation is an important event for fat formation in obesity. Natural compounds that inhibit adipogenic differentiation are frequently screened to develop therapeutic drugs for treating obesity. Here we investigated the effects of phorbaketal A, a natural marine compound, on adipogenic differentiation of mesenchymal stem cells. Phorbaketal A significantly inhibited adipogenic differentiation as indicated by less fat droplets and decreased expression of adipogenic marker genes. The expression of TAZ (transcriptional coactivator with PDZ-binding motif), an inhibitor of adipogenic differentiation, significantly increased during adipogenic differentiation in the presence of phorbaketal A. Phorbaketal A increased the interaction of TAZ and PPARγ to suppress PPARγ (peroxisome proliferator-activated receptor γ) target gene expression. TAZ-depleted cells showed higher adipogenic potential than that of control cells even in the presence of phorbaketal A. During cellular signaling induced by phorbaketal A, ERK (extracellular signal-regulated kinase) played an important role in adipogenic suppression; an inhibitor of ERK blocked phorbaketal A-induced adipogenic suppression. Thus, the results show that phorbaketal A inhibits adipocyte differentiation through TAZ.

Original languageEnglish
Pages (from-to)181-187
Number of pages7
JournalEuropean Journal of Pharmacology
Volume718
Issue number1-3
DOIs
Publication statusPublished - 2013 Sep 26

Fingerprint

Peroxisome Proliferator-Activated Receptors
Genes
Obesity
Extracellular Signal-Regulated MAP Kinases
Fats
phorbaketal A
Metabolic Diseases
Mesenchymal Stromal Cells
Adipocytes
Gene Expression

Keywords

  • Adipogenesis
  • ERK
  • Phorbaketal A
  • PPARγ
  • TAZ

ASJC Scopus subject areas

  • Pharmacology

Cite this

Phorbaketal A inhibits adipogenic differentiation through the suppression of PPARγ-mediated gene transcription by TAZ. / Byun, Mi Ran; Lee, Cham Han; Hwang, Jun Ha; Kim, A. Rum; Moon, Sung Ah; Sung, Mi Kyung; Roh, Jung Rae; Hwang, Eun Sook; Hong, Jeong-Ho.

In: European Journal of Pharmacology, Vol. 718, No. 1-3, 26.09.2013, p. 181-187.

Research output: Contribution to journalArticle

Byun, Mi Ran ; Lee, Cham Han ; Hwang, Jun Ha ; Kim, A. Rum ; Moon, Sung Ah ; Sung, Mi Kyung ; Roh, Jung Rae ; Hwang, Eun Sook ; Hong, Jeong-Ho. / Phorbaketal A inhibits adipogenic differentiation through the suppression of PPARγ-mediated gene transcription by TAZ. In: European Journal of Pharmacology. 2013 ; Vol. 718, No. 1-3. pp. 181-187.
@article{34d2b30e10ce40b39ee70b0d9f202d49,
title = "Phorbaketal A inhibits adipogenic differentiation through the suppression of PPARγ-mediated gene transcription by TAZ",
abstract = "Obesity causes several metabolic diseases, including diabetes. Adipogenic differentiation is an important event for fat formation in obesity. Natural compounds that inhibit adipogenic differentiation are frequently screened to develop therapeutic drugs for treating obesity. Here we investigated the effects of phorbaketal A, a natural marine compound, on adipogenic differentiation of mesenchymal stem cells. Phorbaketal A significantly inhibited adipogenic differentiation as indicated by less fat droplets and decreased expression of adipogenic marker genes. The expression of TAZ (transcriptional coactivator with PDZ-binding motif), an inhibitor of adipogenic differentiation, significantly increased during adipogenic differentiation in the presence of phorbaketal A. Phorbaketal A increased the interaction of TAZ and PPARγ to suppress PPARγ (peroxisome proliferator-activated receptor γ) target gene expression. TAZ-depleted cells showed higher adipogenic potential than that of control cells even in the presence of phorbaketal A. During cellular signaling induced by phorbaketal A, ERK (extracellular signal-regulated kinase) played an important role in adipogenic suppression; an inhibitor of ERK blocked phorbaketal A-induced adipogenic suppression. Thus, the results show that phorbaketal A inhibits adipocyte differentiation through TAZ.",
keywords = "Adipogenesis, ERK, Phorbaketal A, PPARγ, TAZ",
author = "Byun, {Mi Ran} and Lee, {Cham Han} and Hwang, {Jun Ha} and Kim, {A. Rum} and Moon, {Sung Ah} and Sung, {Mi Kyung} and Roh, {Jung Rae} and Hwang, {Eun Sook} and Jeong-Ho Hong",
year = "2013",
month = "9",
day = "26",
doi = "10.1016/j.ejphar.2013.08.035",
language = "English",
volume = "718",
pages = "181--187",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Phorbaketal A inhibits adipogenic differentiation through the suppression of PPARγ-mediated gene transcription by TAZ

AU - Byun, Mi Ran

AU - Lee, Cham Han

AU - Hwang, Jun Ha

AU - Kim, A. Rum

AU - Moon, Sung Ah

AU - Sung, Mi Kyung

AU - Roh, Jung Rae

AU - Hwang, Eun Sook

AU - Hong, Jeong-Ho

PY - 2013/9/26

Y1 - 2013/9/26

N2 - Obesity causes several metabolic diseases, including diabetes. Adipogenic differentiation is an important event for fat formation in obesity. Natural compounds that inhibit adipogenic differentiation are frequently screened to develop therapeutic drugs for treating obesity. Here we investigated the effects of phorbaketal A, a natural marine compound, on adipogenic differentiation of mesenchymal stem cells. Phorbaketal A significantly inhibited adipogenic differentiation as indicated by less fat droplets and decreased expression of adipogenic marker genes. The expression of TAZ (transcriptional coactivator with PDZ-binding motif), an inhibitor of adipogenic differentiation, significantly increased during adipogenic differentiation in the presence of phorbaketal A. Phorbaketal A increased the interaction of TAZ and PPARγ to suppress PPARγ (peroxisome proliferator-activated receptor γ) target gene expression. TAZ-depleted cells showed higher adipogenic potential than that of control cells even in the presence of phorbaketal A. During cellular signaling induced by phorbaketal A, ERK (extracellular signal-regulated kinase) played an important role in adipogenic suppression; an inhibitor of ERK blocked phorbaketal A-induced adipogenic suppression. Thus, the results show that phorbaketal A inhibits adipocyte differentiation through TAZ.

AB - Obesity causes several metabolic diseases, including diabetes. Adipogenic differentiation is an important event for fat formation in obesity. Natural compounds that inhibit adipogenic differentiation are frequently screened to develop therapeutic drugs for treating obesity. Here we investigated the effects of phorbaketal A, a natural marine compound, on adipogenic differentiation of mesenchymal stem cells. Phorbaketal A significantly inhibited adipogenic differentiation as indicated by less fat droplets and decreased expression of adipogenic marker genes. The expression of TAZ (transcriptional coactivator with PDZ-binding motif), an inhibitor of adipogenic differentiation, significantly increased during adipogenic differentiation in the presence of phorbaketal A. Phorbaketal A increased the interaction of TAZ and PPARγ to suppress PPARγ (peroxisome proliferator-activated receptor γ) target gene expression. TAZ-depleted cells showed higher adipogenic potential than that of control cells even in the presence of phorbaketal A. During cellular signaling induced by phorbaketal A, ERK (extracellular signal-regulated kinase) played an important role in adipogenic suppression; an inhibitor of ERK blocked phorbaketal A-induced adipogenic suppression. Thus, the results show that phorbaketal A inhibits adipocyte differentiation through TAZ.

KW - Adipogenesis

KW - ERK

KW - Phorbaketal A

KW - PPARγ

KW - TAZ

UR - http://www.scopus.com/inward/record.url?scp=84887118415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887118415&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2013.08.035

DO - 10.1016/j.ejphar.2013.08.035

M3 - Article

C2 - 24036109

AN - SCOPUS:84887118415

VL - 718

SP - 181

EP - 187

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1-3

ER -